Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

医学 2型糖尿病 二甲双胍 脂肪组织 内科学 糖尿病 临床终点 胰岛素 内分泌学 胃肠病学 临床试验
作者
Amalia Gastaldelli,Kenneth Cusi,Laura Fernández Landó,Ross Bray,Bram Brouwers,Ángel Rodríguez
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:10 (6): 393-406 被引量:328
标识
DOI:10.1016/s2213-8587(22)00070-5
摘要

Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist under development for the treatment of type 2 diabetes. The aim of this substudy was to characterise the changes in liver fat content (LFC), volume of visceral adipose tissue (VAT), and abdominal subcutaneous adipose tissue (ASAT) in response to tirzepatide or insulin degludec in a subpopulation of the SURPASS-3 study. Methods This substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial was done at 45 medical research centres and hospitals across eight countries (Argentina, Austria, Greece, Hungary, Italy, Romania, Spain, and the USA). Eligible participants were adults with type 2 diabetes, a baseline HbA1c 7·0–10·5% (53–91 mmol/mol), a BMI of at least 25 kg/m2, stable weight, were insulin-naive, and on treatment with metformin alone or in combination with a SGLT2 inhibitor for at least 3 months before screening. In addition to the main study inclusion criteria, substudy participants had a fatty liver index of at least 60. Participants had an MRI scan and were randomised (1:1:1:1) in the main study to subcutaneous injection once per week of tirzepatide 5 mg, 10 mg, or 15 mg, or subcutaneous injection once per day of titrated insulin degludec, using an interactive web-response system, and were stratified by country, HbA1c, and concomitant oral anti-hyperglycaemic medication. The primary efficacy endpoint was the change from baseline in LFC (as measured by MRI-proton density fat fraction [MRI-PDFF]) at week 52 using pooled data from the tirzepatide 10 mg and 15 mg groups versus insulin degludec. Analyses were assessed in the enrolled MRI population, which consisted of participants in the modified intention-to-treat population of the main study who also had a valid MRI at either baseline or after baseline. This is a substudy of the trial registered with ClinicalTrials.gov, number NCT03882970, and is complete. Findings From April 1, 2019, to Nov 15, 2019, 502 participants were assessed for eligibility to participate in this substudy, 296 (59%) of whom were included in the enrolled MRI population and randomly assigned to treatment (tirzepatide 5 mg, n=71; tirzepatide 10 mg, n=79; tirzepatide 15 mg, n=72; and insulin degludec, n=74). Baseline demographics and clinical characteristics were similar across all treatment groups. From an overall mean baseline LFC of 15·71% (SD 8·93), the absolute reduction in LFC at week 52 was significantly greater for the pooled tirzepatide 10 mg and 15 mg groups (–8·09%, SE 0·57) versus the insulin degludec group (–3·38%, 0·83). The estimated treatment difference versus insulin degludec was –4·71% (95% CI –6·72 to –2·70; p<0·0001). The reduction in LFC was significantly correlated (p≤0·0006) with baseline LFC (ρ=–0·71), reductions in VAT (ρ=0·29), reductions in ASAT (ρ=0·33), and reductions in body weight (ρ=0·34) in the tirzepatide groups. Interpretation Tirzepatide showed a significant reduction in LFC and VAT and ASAT volumes compared with insulin degludec in this subpopulation of patients with type 2 diabetes in the SURPASS-3 study. These data provide additional evidence on the metabolic effects of this novel dual GIP and GLP-1 receptor agonist. Funding Eli Lilly and Company.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
QZZ关闭了QZZ文献求助
刚刚
lyric发布了新的文献求助20
1秒前
zuhangzhao发布了新的文献求助30
3秒前
3秒前
Gnor完成签到,获得积分10
4秒前
5秒前
Fin2046完成签到,获得积分10
5秒前
张涛完成签到,获得积分10
5秒前
小天完成签到,获得积分10
5秒前
5秒前
小梁发布了新的文献求助10
6秒前
bkagyin应助昏睡的妙梦采纳,获得10
6秒前
7秒前
lan发布了新的文献求助10
7秒前
7秒前
8秒前
8秒前
9秒前
10秒前
李fr发布了新的文献求助10
10秒前
10秒前
memedaaaah发布了新的文献求助10
11秒前
传奇3应助冬去春来采纳,获得10
11秒前
共享精神应助fcyyc采纳,获得30
11秒前
共享精神应助hu采纳,获得10
11秒前
12秒前
12秒前
粉鱼鱼发布了新的文献求助10
12秒前
健忘症发布了新的文献求助10
12秒前
科研小李发布了新的文献求助10
12秒前
13秒前
13秒前
开心发布了新的文献求助10
14秒前
香蕉觅云应助rui采纳,获得10
14秒前
奶油橘子完成签到,获得积分10
14秒前
zuhangzhao完成签到,获得积分10
14秒前
14秒前
汪小南发布了新的文献求助10
15秒前
丘比特应助lyric采纳,获得10
15秒前
15秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975165
求助须知:如何正确求助?哪些是违规求助? 3519595
关于积分的说明 11198781
捐赠科研通 3255912
什么是DOI,文献DOI怎么找? 1798001
邀请新用户注册赠送积分活动 877343
科研通“疑难数据库(出版商)”最低求助积分说明 806298